HEALTH● ELEVATED3h ago · Oct 8, 2026, 2:33 AM
FDA: Mifepristone review won’t be done until March
The Hill · north america
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the…
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH48m agoMenopause patients left without treatment: what is happening in Spain?EuroNews [en]HEALTH1h agoBenedetta Bolognesi, biotechnologist: “In Alzheimer’s, proteins can start accumulating twenty years before symptoms appear”ClarínHEALTH5h agoRussia dismisses reports of second plague case as ‘false information’Al Jazeera [en]HEALTH5h agoPsychology experts agree: retirees who do these 11 things will almost always have happier moments as they ageClarín